+1-518-621-2074 | US-Canada Toll Free Contact Us

Geriatrics and Smokers Driving Asia Pacific COPD Therapeutics Market

about us

Published on : Jan 10, 2018

ALBANY, New York, Jan 10, 2018: ResearchMoz.us announces the acquisition and availability of a fresh business intelligence study on the market for chronic obstructive pulmonary disease (COPD) therapeutics in the region of Asia Pacific. The report, titled “COPD Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Novel Therapies,” is a product developed by healthcare and commerce research professionals and aspires to act as a decision-making tool for targeted audiences such as healthcare providers, research institutes, and government agencies. Beginning with a crisp introduction of the current condition of the COPD therapeutics market in APAC, the report throws light on diseases such as epidemiology and their symptoms, etiology and pathophysiology and their diagnosis, and treatment options.

Some of the key products evaluated by the analysts of the report are related to bronchodilator combination therapy including Brimica or Duaklir Genuair (aclidinium or formoterol) by AstraZeneca, Spiolto or Stiolto Respimat (tiotropium or olodaterol) by Boehringer Ingelheim, Ultibro (glycopyrronium or indacaterol) by Novartis, Anoro Ellipta (umeclidinium or vilanterol) by GlaxoSmithKline, and Combivent (ipratropium or albuterol) by Boehringer Ingelheim, bronchodilator and inhaled corticosteroid combination therapy including Symbicort by AstraZeneca, Seretide or Advair or Adoair and Relvar by GlaxoSmithKline, bronchodilator monotherapy including Spiriva by Boehringer Ingelheim, Foradil by Novartis, Onbrez or Arbeela or Arcapta, Seebri or Tovanor by Novartis, and Striverdi Respimat by  Boehringer Ingelheim, and alternative therapy including Daxas or Daliresp by Nycomeds.

Get SAMPLE REPORT PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1434918

The report reviews a number of pipeline distribution on the basis of stage of development, molecule, program type, and route of administration. Some of the promising pipeline candidates highlighted under the study are Mepolizumab by GlaxoSmithKline, Benralizumab by AstraZeneca and MedImmune, PT003 by AstraZeneca and Pearl Therapeutics, PT010 by AstraZeneca and Pearl Therapeutics, Fluticasone Furoate, Umeclidinium Bromide and Vilanterol Trifenatate by GlaxoSmithKline, and CHF-5993 (beclometasone dipropionate or formoterol fumarate or glycopyrronium bromide) by Chiesi Farmaceutici S.p.A.

The chapter on clinical trial analysis explores failure rate both by phase and molecule type, clinical trial size in terms of patient enrollment per product and trial by molecule type, molecular target, and phase, and clinical trial duration on the basis of molecule type and target.

Geographically, the report takes stock of the treatment usage patterns, annual cost of therapy, and overall market size in the countries of India, China, Australia, South Korea, and Japan. The analysts of the report assert that current active pipeline, promising late stage pipeline products, and increasing awareness regarding COPD will keep the market for COPD in good stead in the region of Asia Pacific. It has been observed that geriatrics are more at the risk of breathing disorders and a substantial chunk of them suffer from it each year. Increased cases of smoking is only expected to further add to the patient base. The launch of new products and approval of novel drugs are expected to fuel the Asia Pacific COPD therapeutics market.

On the other hand, sales erosion by generics, low diagnosis rates, and growing competition are a few obstructions curtailing the progress of the Asia Pacific COPD therapeutics market. As of now, Roflumilast remains the only targeted therapy drug currently being sold in the market despite substantial anti-inflammatory effects. Its proliferation remains limited owing to its side effects.

The chapter of the report on deals and strategic consolidations elaborates the number of disclosed and undisclosed deals by year, aggregate deal value, potential of the deal on the basis of stage of development, molecule type, and molecular target.

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]